相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The digestive neuronal-glial-epithelial unit: a new actor in gut health and disease
Michel Neunlist et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Alteration in P-glycoprotein Functionality Affects Intrabrain Distribution of Quinidine More Than Brain Entry-A Study in Rats Subjected to Status Epilepticus by Kainate
Stina Syvanen et al.
AAPS JOURNAL (2012)
Blood-brain barrier P-glycoprotein function in Alzheimer's disease
Danielle M. E. van Assema et al.
BRAIN (2012)
Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: Implications for clinical disease
Helga E. de Vries et al.
EPILEPSIA (2012)
Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis
Soo Young Kim et al.
EPILEPSIA (2012)
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
Gregory Porras et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease
Valerio Pisani et al.
JOURNAL OF NEUROINFLAMMATION (2012)
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease
Philippe Huot et al.
NEUROPHARMACOLOGY (2012)
Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesia
K. Elisabet Ohlin et al.
BRAIN (2011)
Priorities in Parkinson's disease research
Wassilios G. Meissner et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents
Chun-Jung Lin et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease
Kevin J. Black et al.
JOURNAL OF NEUROSCIENCE (2010)
Dopamine Transporter Binding Is Unaffected by L-DOPA Administration in Normal and MPTP-Treated Monkeys
Pierre-Olivier Fernagut et al.
PLOS ONE (2010)
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia
Stefania Fasano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Lentiviral Overexpression of GRK6 Alleviates L-Dopa-Induced Dyskinesia in Experimental Parkinson's Disease
Mohamed R. Ahmed et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
The blood-brain barrier in brain homeostasis and neurological diseases
Nicolas Weiss et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2009)
Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease
Olivier Berton et al.
BIOLOGICAL PSYCHIATRY (2009)
Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept
Andreas Reichel
CHEMISTRY & BIODIVERSITY (2009)
Blood-brain barrier alterations in ageing and dementia
Bogdan O. Popescu et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates-Evidence from in vivo neuroimaging studies
Arnar Astradsson et al.
NEUROBIOLOGY OF DISEASE (2009)
Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism
T. Chaumette et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2009)
Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid
Christian Hoecht et al.
NEUROSCIENCE LETTERS (2009)
Combined 5-HTIA and 5-HTIB receptor agonists for the treatment of L-DOPA-induced dyskinesia
Ana Munoz et al.
BRAIN (2008)
CSF as a surrogate for assessing CNS exposure: An industrial perspective
Jiunn H. Lin
CURRENT DRUG METABOLISM (2008)
Strategies to assess blood-brain barrier penetration
Li Di et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease
Shigeki Hirano et al.
JOURNAL OF NEUROSCIENCE (2008)
Several major antiepileptic drugs are substrates for human P-glycoprotein
Carlos Luna-Tortos et al.
NEUROPHARMACOLOGY (2008)
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys
Xuebing Cao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease
Dieter Scheller et al.
EXPERIMENTAL NEUROLOGY (2007)
Blood-brain barrier delivery
William M. Pardridge
DRUG DISCOVERY TODAY (2007)
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia
Jenny E. Westin et al.
JOURNAL OF NEUROSCIENCE (2006)
5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease
Erwan Bezard et al.
NEUROBIOLOGY OF DISEASE (2006)
Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease
Keiichirou Wada et al.
NEUROREPORT (2006)
Transport of carbamazepine and drug interactions at blood-brain barrier
JJ Sun et al.
ACTA PHARMACOLOGICA SINICA (2006)
The role of blood-brain barrier studies in the pharmaceutical industry
A Reichel
CURRENT DRUG METABOLISM (2006)
Carbamazepine uptake into rat brain following intra-olfactory transport
NS Barakat et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2006)
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
PM Carvey et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
Neuropharmacokinetics of a new α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat
F Bourasset et al.
DRUG METABOLISM AND DISPOSITION (2005)
The blood-brain barrier/neurovascular unit in health and disease
BT Hawkins et al.
PHARMACOLOGICAL REVIEWS (2005)
L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain
E Bezard et al.
NEUROBIOLOGY OF DISEASE (2005)
Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo
R Kortekaas et al.
ANNALS OF NEUROLOGY (2005)
Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian
C Barcia et al.
JOURNAL OF NEURAL TRANSMISSION (2005)
The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model
A Doran et al.
DRUG METABOLISM AND DISPOSITION (2005)
Statins in stroke prevention and carotid atherosclerosis -: Systematic review and up-to-date meta-analysis
P Amarenco et al.
STROKE (2004)
Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics
DD Shen et al.
ADVANCED DRUG DELIVERY REVIEWS (2004)
Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets
J Zhang et al.
BRAIN RESEARCH (2003)
Alzheimer disease in the US population - Prevalence estimates using the 2000 census
LE Hebert et al.
ARCHIVES OF NEUROLOGY (2003)
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
MR Law et al.
BRITISH MEDICAL JOURNAL (2003)
1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3
TS Shang et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery
JC Kalvass et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2002)
P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain
H Potschka et al.
NEUROREPORT (2001)
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
E Bezard et al.
NATURE REVIEWS NEUROSCIENCE (2001)
Carbamazepine is not a substrate for P-glycoprotein
A Owen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma
WS Kim et al.
INVESTIGATIONAL NEW DRUGS (2001)
Comparison by microdialysis of striatal L-DOPA after its systemic administration in rats with probes implanted acutely or through a guide cannula
A Marburger et al.
JOURNAL OF NEUROSCIENCE METHODS (2000)
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
H Shimura et al.
NATURE GENETICS (2000)
Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine
MC Walker et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
